Shire PLC has acquired the rights to develop and market the gastrointestinal drug Resolor in the United States in an agreement with Janssen Pharmaceutica N.V.


Shire, Resolor, Janssen Pharmaceutica, prucalopride, chronic constipation, gastrointestinal drug, Roger Adsett


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Shire acquires U.S. rights to Resolor

January 10th, 2012

PHILADELPHIA – Shire PLC has acquired the rights to develop and market the gastrointestinal drug Resolor in the United States in an agreement with Janssen Pharmaceutica N.V.

Shire said Tuesday that under the terms of the agreement, the U.S. rights to the Resolor trademark will be transferred to the company.

Resolor (prucalopride), a treatment for chronic constipation, isn't currently approved by the Food and Drug Administration for use in the United States.

"We are excited about the opportunity to develop Resolor in the U.S., and we look forward to working with the FDA and the GI physician community to define the path forward for registration of the medicine as a treatment for chronic constipation in the U.S.," stated Roger Adsett, senior vice president of Shire's global GI business.

Currently, Resolor is available in Germany, Ireland, Belgium, France, Greece and the United Kingdom and will be commercially available in Italy in mid-January, according to Shire. Additional launches throughout Europe are planned for 2012.

Advertisement